Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 3, 2008, Pages 319-329

  Moosmann, Nicolas ^a   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cetuximab; Colorectal cancer; EGF receptor; FOLFOX; Oxaliplatin

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PLATINUM COMPLEX; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; GENE MUTATION; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; LUNG RESECTION; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PROGNOSIS; PROTEIN EXPRESSION; REPEATED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 45249086561     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.3.319     Document Type: Review

References (58)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol. 10(6), 896-903 (1992).
3. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol. 16(1), 301-308 (1998).
4. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. 22(18), 3766-3775 (2004).
5. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209), 1041-1047 (2000).
6. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22(1), 23-30 (2004).
7. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(16), 2938-2947 (2000).
8. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004).
9. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343(13), 905-914 (2000).
10. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22(7), 1209-1214 (2004).
11. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005).
12. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21(14), 2787-2799 (2003).
13. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
14. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol. 23(16), 3697-3705 (2005).
15. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007).
16. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
17. Wilke H, Glynne-Jones R, Thaler J et al. MABEL - a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. J. Clin. Oncol. 25(Suppl. 18), 3549 (2006).
18. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040-2048 (2007).
19. Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: the CRYSTAL trial. J. Clin. Oncol. 25(Suppl. 18), 4000 (2007).
20. Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/ FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer: OPUS, a randomized Phase II study. J. Clin. Oncol. 25(Suppl. 18) 4035 (2007).
21. Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25(13), 1658-1664 (2007).
22. Saltz LB, Rosen LS, Marshall JL et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 25(30), 4793-4799 (2007).
23. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 19(Suppl. 18), S32-S40 (2001).
24. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353(2), 172-187 (2005).
25. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl. 4) S9-S15 (2001).
26. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1(11), 1311-1318 (1995).
27. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98(8), 1275-1280 (2007).
28. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity ofanti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. 8(5), 994-1003 (2002).
29. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann. Oncol. 14(Suppl. 2) ii13-ii16 (2003).
30. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 25(2 Suppl. 5), 4-12 (1998).
31. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J. Clin. Oncol. 24(3), 394-400 (2006).
32. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. 29(5 Suppl. 15), 11-20 (2002).
33. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin. Oncol. 30(4 Suppl. 15), 5-13 (2003).
34. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N. Engl. J. Med. 350(23), 2343-2351 (2004).
35. de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J. Clin. Oncol. 25(Suppl. 18) 4007 (2007).
36. Nordlinger B, Sorbye H, Collette L et al. Final results of the EORTC intergroup randomized phase III study 40983 evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J. Clin. Oncol. 25(Suppl. 18), LBA5 (2007).
37. Prewett M, Bassi R, Carrick F et al. Cetuximab (Erbitux) enhances clinical efficacy of oxaliplatin in human colon carcinoma xenografts and reverses oxaliplatin resistance. Presented at: 2005 AACR-NCI-EORTC Annual Meeting. Philadelphia, PA, USA, 14-18 November, 2005.
38. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res 6(6), 2166-2174 (2000).
39. Dittmann K, Mayer C, Fehrenbacher B et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 280(35), 31182-31189 (2005).
40. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127-137 (2001).
41. Tabernero J, Van Cutsem E, Diaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25(33), 5225-5232 (2007).
42. Colucci G, Giuliani F, Mattioli R et al. FOLFOX-4 plus cetuximab in untreated patients with advanced colorectal cancer. A Phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). J. Clin. Oncol. 24(Suppl. 18), 3559 (2006).
43. Dakhil S, Cosgriff T, Headley D, Boccia R, Badarinath S. Cetuximab plus FOLFOX6 as first line therapy for metastatic colorectal cancer (an International Oncology Network study, I-03-002). J. Clin. Oncol. 24(Suppl. 18) 3557 (2006).
44. Dittrich C, Hoehler T, Lordick F et al. A Phase I/II study of cetuximab in combination with 5-fluorouracil/folinic acid plus weekly oxaliplatmi (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR). Preliminary results. Ann Oncol. 17(24 Suppl.), O-019 (2006).
45. Borner M, Mingrone W, Koeberle D et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol. 24(Suppl. 18) 3551 (2006).
46. Heinemann V, Fischer von Weikersthal L, Moosmann N et al. Cetuximab plus capecitabine plus irinotecan versus cetuximab plus capecitabine plus oxaliplatin as first line therapy for patients with metastatic colorectal cancer: preliminary results of a randomized Phase II trial of the AIO study group. J. Clin. Oncol. 24(Suppl. 18) 3550 (2006).
47. Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX) +/- cetuximab (C225) for patients (pts) with untreated metastatic adeno carcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results. J. Clin. Oncol. 24(Suppl. 18) 3509 (2006).
48. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol. 16(8), 1311-1319 (2005).
49. Polikoff J, Mitchell E, Badarinath S et al. Erbitux (cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized Phase III-trial. J. Clin. Oncol. 23(Suppl.), 3574 (2005).
50. Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J. Clin. Oncol. 24(31), 4976-4982 (2006).
51. Hecht JR, Chidiac T, Mitchell E et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab for metastatic colorectal cancer. Presanted at: World Congress on Gastrointestinal Cancer (WCGI). Barcelona, Spain, 27-30 June, 2007.
52. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. 23(22), 5235-5246 (2005).
53. Segaert S, Tabernero J, Chosidow O et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J. Dtsch Dermatol. Ges. 3(8), 599-606 (2005).
54. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol. 16(9), 1425-1433 (2005).
55. Saltz L, Kies MS, Abbruzzese JL, Azarnia N, Needle MN. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. 22, 817 (2003).
56. Saltz LB, Meropol NJ, Loehrer PJ Sr. Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004).
57. Lievre A, Bachet JB, Le Corte D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
58. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230-3237 (2007).